title: [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
abstract: OBJECTIVE
  To evaluate the efficacy and safety of high doses of thymopentin (10 mg/d) combined with transartery chemoembolization for primary liver cancer.
  
  
  METHODS
  Fifty primary liver cancer patients were randomly divided into two groups: therapeutic and control group, and all were treated with transfemoral artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5-Fu 750 mg, CF 300 mg and lipiodol 20 ml. Therapeutic group (25) were added 10 mg thymopentin daily after TACE: i.v. on dl - d5, and im on D6 - D21.
  
  
  RESULTS
  There was a significant difference in adverse effect and toxicity such as naupathia,fever, swirl, asthenia observed between two groups (P < 0.05). No difference in either pre- or post-chemotherapy peripheral blood examination and biochemical assay was found between two groups (P > 0.05). In control group, CD4+ cell was 37.92% +/- 8.71% in pre-treatment, which decreased to 29.16% +/- 8.21% in post-treatment with a significant difference (P < 0.01), whereas there was no evident difference in CD4+ cell between pre-treatment and post-treatment in the treatment group.
  
  
  CONCLUSIONS
  Transartery chemoembolization combined with high dose of thymopentin in the treatment for primary liver cancer is effective and safe, and can significantly improve the immune function and the chemotherapy tolerance.
authors.affiliation: Sichuan University, Chengdu 610065, China. litaoxmf@126.com
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Zheng-Wen
authors.initials: ZW
authors.lastname: Li
authors.forename: Hua-Chang
authors.initials: HC
authors.lastname: Wen
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001247:Asthenia / Q000139:chemically induced; D015496:CD4-Positive T-Lymphocytes; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005334:Fever / Q000139:chemically induced; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000628:therapy*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D012074:Remission Induction; D015996:Survival Rate; D016305:Thymopentin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D015251:Epirubicin; D007459:Iodized Oil; D016305:Thymopentin; D005472:Fluorouracil